PE20160123A1 - Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio - Google Patents

Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio

Info

Publication number
PE20160123A1
PE20160123A1 PE2015001987A PE2015001987A PE20160123A1 PE 20160123 A1 PE20160123 A1 PE 20160123A1 PE 2015001987 A PE2015001987 A PE 2015001987A PE 2015001987 A PE2015001987 A PE 2015001987A PE 20160123 A1 PE20160123 A1 PE 20160123A1
Authority
PE
Peru
Prior art keywords
improve
methods
meibo
meibomian glands
quality
Prior art date
Application number
PE2015001987A
Other languages
English (en)
Inventor
Michael B Gross
S Gregory Smith
Olav E Sandnes
Original Assignee
Physicians Recommended Nutriceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49947054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Physicians Recommended Nutriceuticals Llc filed Critical Physicians Recommended Nutriceuticals Llc
Publication of PE20160123A1 publication Critical patent/PE20160123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion hace referencia a metodos para mejorar la capa lipidica de la lagrima e incrementar el tiempo de ruptura lagrimal por medio de la elevacion del indice de omega-3 en pacientes que sufren de los sintomas del ojo seco, blefaritis posterior y/o disfuncion de las glandulas de meibomio
PE2015001987A 2013-03-12 2014-02-05 Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio PE20160123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/815,599 US9381183B2 (en) 2012-07-18 2013-03-12 Methods for improving the quality of the meibum composition of meibomian glands

Publications (1)

Publication Number Publication Date
PE20160123A1 true PE20160123A1 (es) 2016-03-03

Family

ID=49947054

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001987A PE20160123A1 (es) 2013-03-12 2014-02-05 Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio

Country Status (10)

Country Link
US (1) US9381183B2 (es)
EP (1) EP2968243B1 (es)
JP (2) JP6538022B2 (es)
KR (1) KR101904850B1 (es)
CN (1) CN105358142A (es)
CA (1) CA2904737C (es)
CL (1) CL2015002713A1 (es)
ES (1) ES2743614T3 (es)
PE (1) PE20160123A1 (es)
WO (1) WO2014158356A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US9115078B2 (en) * 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
CN103998034A (zh) 2011-09-12 2014-08-20 塔索斯·乔治欧 ω脂肪酸用于治疗疾病的用途
EP2862439A4 (en) * 2012-06-19 2016-04-13 Santen Pharmaceutical Co Ltd METHOD FOR MODIFYING THE STATUS OF ANIMALS WITHOUT HAIR
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
JP6497812B2 (ja) * 2013-06-28 2019-04-10 学校法人慶應義塾 マイボーム腺機能不全の処置剤
AU2015269353B2 (en) * 2014-06-04 2020-03-26 Tersus Pharmaceuticals, LLC Methods of treating chronic dry eye disease using C16:1n7 palmitoleate and derivatives thereof
WO2018005685A1 (en) * 2016-06-29 2018-01-04 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
WO2021148845A1 (en) * 2020-01-23 2021-07-29 Visufarma S.P.A. Ophthalmic composition for the treatment of dry eye disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6353022B1 (en) 1999-11-09 2002-03-05 Alcon Universal Ltd. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US20060127505A1 (en) 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20040076695A1 (en) 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US6649195B1 (en) 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US7041840B2 (en) 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20060009522A1 (en) * 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
DE202004015931U1 (de) 2004-10-13 2005-01-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
EP1962618A2 (en) 2005-12-20 2008-09-03 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US20100048705A1 (en) 2006-11-09 2010-02-25 Children's Medical Center Corporation Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids
EP1932521A1 (en) 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
EP1932520A1 (en) 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
US20090226547A1 (en) 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
US20100093648A1 (en) 2008-10-09 2010-04-15 Antonio Cruz Treatment of macular degeneration-related disorders
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
JP2013510095A (ja) * 2009-11-06 2013-03-21 アルコン リサーチ， リミテッド ドライアイの軽減のための栄養サプリメント
RU2012134351A (ru) * 2010-01-11 2014-02-20 ДЖиТиЭкс, ИНК. Способы лечения дисфункции мейбомиевых желез
WO2012067224A1 (ja) * 2010-11-19 2012-05-24 日本水産株式会社 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤
CA2738357C (en) 2011-04-07 2019-08-06 Amerisciences, Lp Methods and compositions to promote ocular health

Also Published As

Publication number Publication date
EP2968243B1 (en) 2019-06-19
CN105358142A (zh) 2016-02-24
KR20150126405A (ko) 2015-11-11
ES2743614T3 (es) 2020-02-20
US20140024625A1 (en) 2014-01-23
KR101904850B1 (ko) 2018-10-08
CA2904737A1 (en) 2014-10-02
EP2968243A4 (en) 2016-09-14
WO2014158356A1 (en) 2014-10-02
CA2904737C (en) 2019-11-26
JP2019058194A (ja) 2019-04-18
CL2015002713A1 (es) 2016-09-30
JP2016512245A (ja) 2016-04-25
US9381183B2 (en) 2016-07-05
JP6538022B2 (ja) 2019-07-03
EP2968243A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
PE20160123A1 (es) Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CR20150316A (es) Compuestos y sus métodos de empleo
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY37098A (es) Moduladores de ror-gamma
CR20160561A (es) Variantes del anticuerpo anti-factor d y sus usos
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
ECSP14030779A (es) Inhibidores del nampt
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
UY37038A (es) Composiciones y métodos para disminuir la expresión de tau
CR20160290A (es) Inhibidores tetracíclicos de autotaxina